Skip to main content
Clinical Trials/TCTR20170515002
TCTR20170515002
Completed
N/A

The Efficacy of Tibial nerve block and Obturator nerve block combined with Continuous adductor canal block after Total knee arthroplasty : A Randomized controlled trial.

none0 sites90 target enrollmentMay 15, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
total knee arthroplastycontinuous adductor canal blockobturator nerve blocktibial nerve block
Sponsor
none
Enrollment
90
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 15, 2017
End Date
May 29, 2017
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
none

Eligibility Criteria

Inclusion Criteria

  • patient who was scheduled for total knee arthroplasty at King Chulalongkorn Memorial Hospital
  • American Society of anesthesiologist ASA class 1 to 3
  • o ASA class 1 A normal healthy patient non smoking no or minimal alcohol use
  • o ASA class 2 A patient with mild systemic disease Mild diseases only without substantive functional limitations Examples include but not limited to current smoker social alcohol drinker pregnancy obesity 30 BMI 40 well controlled DM HTN mild lung disease
  • o ASA class 3 A patient with severe systemic disease but not threaten to life poorly controlled DM or HTN COPD morbid obesity BMI 40 active hepatitis alcohol dependence or abuse implanted pacemaker moderate reduction of ejection fraction ESRD undergoing regularly scheduled dialysis premature infant PCA 60 weeks history 3 months of MI CVA TIA or CAD stents
  • o Body mass index (BMI) between 18 to 40 kg/m2

Exclusion Criteria

  • o refuse to participate this study
  • o allergy to any drug in this study
  • o contraindication to neuraxial anesthesia eg.coagulopathy
  • o contraindication to NSAIDs (Dynastat and Celebrex in this study) for example history of heart failure, cerebrovascular disease, heart or coronary artery surgery, history of peptic ulcer, abnormality of liver enzyme, liver or renal failure, organ transplantation and coagulopathy.
  • o chronic opioids use (definition : daily or almost opioids use for more than three months or morphine use more than 60 miligrams per day for more than 1 months) or diagnosed of neuropathic pain
  • o unable to performed Time up and go test

Outcomes

Primary Outcomes

Not specified

Similar Trials